Cross Country Healthcare (CCRN) 10-Q 5 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 31, 2016
Document and Entity Information [Abstract]
Trading Symbol	CCRN
Entity Registrant Name	CROSS COUNTRY HEALTHCARE INC
Entity Central Index Key	1,141,103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		32,984,741

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 10,229	$ 2,453
Accounts receivable, net of allowances of $3,577 in 2016 and $4,045 in 2015	144,611	146,873
Prepaid expenses	5,070	4,521
Insurance recovery receivable	2,811	2,866
Other current assets	1,714	2,032
Total current assets	164,435	158,745
Property and equipment, net of accumulated depreciation of $41,194 in 2016 and $39,368 in 2015	11,018	10,470
Goodwill	77,376	95,096
Intangible assets, net of accumulated amortization of $42,567 in 2016 and $39,754 in 2015 (excluding goodwill)	73,510	82,914
Debt issuance costs, net	1,017	376
Other non-current assets	17,010	17,994
Total assets	344,366	365,595
Current liabilities:
Accounts payable and accrued expenses	38,224	41,098
Accrued compensation and benefits	28,964	29,402
Current portion of long-term debt and capital lease obligations	2,033	8,071
Deferred purchase price	0	2,184
Other current liabilities	4,701	5,291
Total current liabilities	73,922	86,046
Long-term debt and capital lease obligations, less current portion	77,738	81,301
Non-current deferred tax liabilities	12,188	18,475
Long-term accrued claims	28,532	30,070
Contingent consideration	2,754	3,533
Other long-term liabilities	4,955	4,826
Total liabilities	200,089	224,251
Commitments and contingencies
Stockholders' equity:
Common stock	3	3
Additional paid-in capital	255,310	254,108
Accumulated other comprehensive loss	(1,234)	(1,207)
Accumulated deficit	(110,272)	(112,056)
Total Cross Country Healthcare stockholders' equity	143,807	140,848
Noncontrolling interest	470	496
Total stockholders' equity	144,277	141,344
Total liabilities and stockholders' equity	$ 344,366	$ 365,595

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 3,577	$ 4,045
Property and equipment, accumulated depreciation	41,194	39,368
Other intangible assets, accumulated amortization	41,232	38,419
Other Intangible Assets [Member]
Other intangible assets, accumulated amortization	$ 42,567	$ 39,754

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue from services	$ 199,443	$ 192,617	$ 396,026	$ 378,581
Operating expenses:
Direct operating expenses	144,597	144,254	290,134	283,181
Selling, general and administrative expenses	44,675	40,891	87,608	82,057
Bad debt expense	228	131	477	222
Depreciation	1,059	989	2,064	1,949
Amortization	1,406	983	2,813	1,965
Acquisition-related contingent consideration	183	0	470	0
Acquisition and integration costs	0	40	0	158
Restructuring costs	0	1,007	0	1,007
Impairment charges	24,311	0	24,311	0
Total operating expenses	216,459	188,295	407,877	370,539
(Loss) income from operations	(17,016)	4,322	(11,851)	8,042
Other expenses (income):
Interest expense	1,608	1,772	3,243	3,509
Loss (gain) on derivative liability	3,571	(362)	(12,865)	(2,509)
Loss on early extinguishment of debt	1,568	0	1,568	0
Other (income) expense, net	(34)	27	(51)	70
(Loss) income before income taxes	(23,729)	2,885	(3,746)	6,972
Income tax (benefit) expense	(6,634)	205	(5,837)	1,242
Consolidated net (loss) income	(17,095)	2,680	2,091	5,730
Less: Net income attributable to noncontrolling interest in subsidiary	142	107	306	223
Net (loss) income attributable to common shareholders	$ (17,237)	$ 2,573	$ 1,785	$ 5,507
Net (loss) income per share attributable to common shareholders - Basic
Net income (loss) per share attributable to common shareholders - Basic (in dollars per share)	$ (0.54)	$ 0.08	$ 0.06	$ 0.18
Net (loss) income per share attributable to common shareholders - Diluted
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ (0.54)	$ 0.08	$ (0.26)	$ 0.13
Weighted average common shares outstanding:
Basic (shares)	32,085	31,398	32,021	31,346
Diluted (shares)	32,085	32,040	36,194	35,508

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Consolidated net (loss) income	$ (17,095)	$ 2,680	$ 2,091	$ 5,730
Other comprehensive loss, before income tax:
Unrealized foreign currency translation loss	(20)	(32)	(27)	(18)
Other comprehensive loss, before income taxes	(20)	(32)	(27)	(18)
Income tax (benefit) expense related to items of other comprehensive loss	0	0	0	0
Other comprehensive loss, net of tax	(20)	(32)	(27)	(18)
Comprehensive (loss) income	(17,115)	2,648	2,064	5,712
Less: Net income attributable to noncontrolling interest in subsidiary	142	107	306	223
Comprehensive (loss) income attributable to common shareholders	$ (17,257)	$ 2,541	$ 1,758	$ 5,489

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Consolidated net (loss) income	$ 2,091	$ 5,730
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,877	3,914
Impairment charges	24,311	0
Amortization of debt discount and debt issuance costs	902	936
Provision for allowances	2,254	642
Loss on early extinguishment of debt	1,568	0
Deferred income tax (benefit) expense	(6,288)	1,412
Gain on derivative liability	(12,865)	(2,509)
Acquisition-related contingent consideration	470	0
Equity compensation	1,767	1,216
Other non-cash costs	5	19
Changes in operating assets and liabilities:
Accounts receivable	9	(8,134)
Prepaid expenses and other assets	565	1,458
Income taxes	(665)	(329)
Accounts payable and accrued expenses	(5,007)	1,190
Other liabilities	(1,127)	452
Net cash provided by operating activities	12,867	5,997
Cash flows from investing activities
Acquisition-related settlements - Medical Staffing Network	(2,155)	0
Acquisition-related settlements - Mediscan	297	0
Purchases of property and equipment	(2,616)	(1,033)
Net cash used in investing activities	(4,474)	(1,033)
Cash flows from financing activities
Proceeds from borrowing on Senior Credit Facility	40,000	0
Debt issuance costs	(990)	0
Principal payments on Second Lien Term Loan	(30,000)	0
Extinguishment fees	(641)	0
Repayments on Senior Secured Asset-Based revolving credit facility	(65,200)	(34,800)
Borrowings under Senior Secured Asset-Based revolving credit facility	57,200	34,300
Repayments of capital lease obligations	(47)	(53)
Cash paid for shares withheld for taxes	(565)	(465)
Payment of contingent consideration	(17)	0
Cash payment to noncontrolling shareholder	(332)	(247)
Net cash used in financing activities	(592)	(1,265)
Effect of exchange rate changes on cash	(25)	(15)
Change in cash and cash equivalents	7,776	3,684
Cash and cash equivalents at beginning of period	2,453	4,995
Cash and cash equivalents at end of period	$ 10,229	$ 8,679

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the "Company"). The condensed consolidated financial statements include all assets, liabilities, revenue, and expenses of InteliStaf of Oklahoma, LLC, which is controlled by the Company but not wholly-owned. The Company records the ownership interest of the noncontrolling shareholder as noncontrolling interest in subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 . These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The December 31, 2015 condensed consolidated balance sheet included herein was derived from the December 31, 2015 audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K. Certain prior period amounts have been reclassified to conform to the current period presentation. See Note 11 - Segment Data.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, the valuation of accounts receivable, goodwill and intangible assets, other long-lived assets, share-based compensation, accruals for health, workers’ compensation and professional liability claims, valuation of deferred tax assets and the purchase price allocation, derivative liability, legal contingencies, future contingent considerations, income taxes and sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncement In September 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Prior to the issuance of the ASU, entities were required to retrospectively apply adjustments made to provisional amounts recognized in a business combination. The Company adopted this guidance in the first quarter of 2016, with no impact on its financial position and results of operations upon adoption. This new guidance may impact the Company for potential measurement adjustments related to its 2015 acquisition. See Note 3 - Acquisitions. In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40), Customers Accounting for Fees Paid in a Cloud Computing Arrangement , to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license element, then the customer should account for the software license element arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company prospectively adopted this guidance in the first quarter of 2016, with no impact on adoption. In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs . This guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The Company adopted this guidance in the first quarter of 2016, and reclassified $0.5 million of the Company's net debt issuance costs to long-term debt and capital lease obligations in its condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015 .

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS Mediscan On October 30, 2015, the Company completed the acquisition of all of the membership interests of New Mediscan II, LLC, Mediscan Diagnostic Services, LLC, and Mediscan Nursing Staffing, LLC (collectively "Mediscan") for a purchase price of $29.9 million in cash ( $28.0 million plus working capital estimate) and $4.7 million in shares (or 349,871 shares) of the Company's Common Stock, subject to a net working capital adjustment. In the first quarter of 2016, the net working capital adjustment was settled consistent with the receivable balance as of December 31, 2015. The sellers are also eligible to receive an earnout based on Mediscan's 2016 and 2017 performance that could provide up to an additional $7.0 million of cash. As of June 30, 2016, a total of $4.1 million was estimated as the fair value for this contingent consideration and accordingly, is included in other current liabilities and contingent consideration on the condensed consolidated balance sheets. See Note 9 - Fair Value Measurements. The shares of Common Stock issued in connection with the acquisition were subject to a lockup period, which ended April 30, 2016. The acquisition has been accounted for in accordance with FASB ASC 805, Business Combinations, using the acquisition method of accounting. Mediscan's results of operations are included in the consolidated statements of operations from October 30, 2015 and have been included in the Company's Nurse and Allied Staffing business segment. As such, the associated goodwill related to the acquisition is fully allocated to Nurse and Allied Staffing. Medical Staffing Network On June 30, 2014, the Company acquired substantially all of the assets and certain liabilities of Medical Staffing Network Healthcare, LLC (MSN). Of the purchase price, $2.5 million was deferred and due to the seller 21 months from the acquisition date, less any COBRA expenses incurred by the Company on behalf of former MSN employees over that period. The Company incurred $0.4 million in COBRA expenses since the MSN acquisition and, on April 1, 2016, released to the seller the remaining liability of $2.1 million . Pro Forma Financial Information The following unaudited pro forma financial information approximates the consolidated results of operations of the Company as if the Mediscan acquisition had occurred as of January 1, 2015, after giving effect to certain adjustments, including additional interest expense on the amount the Company borrowed on the date of the transaction, the amortization of acquired intangible assets, and the elimination of certain expenses that will not be recurring in post-acquisition periods, net of an estimated income tax impact. These results are not necessarily indicative of future results as they do not include incremental investments in support functions, elimination of costs for integration or operating synergies or an estimate of any impact on interest expense resulting from the operating cash flow of the acquired business, among other adjustments that could be made in the future but are not factually supportable on the date of the transaction. Six Months Ended June 30, 2015 (unaudited, amounts in thousands) Revenue from services $ 399,389 Net income attributable to common shareholders $ 6,629 Net income per share attributable to common shareholders - Basic $ 0.21 Net income per share attributable to common shareholders - Diluted $ 0.16

COMPREHENSIVE INCOME (LOSS)

COMPREHENSIVE INCOME (LOSS)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
COMPREHENSIVE INCOME (LOSS)	COMPREHENSIVE INCOME (LOSS) Total comprehensive income (loss) includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes. Certain of the Company’s foreign subsidiaries use their respective local currency as their functional currency. In accordance with the Foreign Currency Matters Topic of the FASB ASC, assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was approximately $1.2 million at both June 30, 2016 and December 31, 2015 . There was no income tax impact related to foreign currency translation adjustments for the three and six months ended June 30, 2016 and June 30, 2015 .

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 (amounts in thousands, except per share data) Numerator: Net income attributable to common shareholders - Basic $ (17,237 ) $ 2,573 $ 1,785 $ 5,507 Interest on Convertible Notes * * 1,677 1,667 Gain on derivative liability * * (12,865 ) (2,509 ) Net income attributable to common shareholders - Diluted $ (17,237 ) $ 2,573 $ (9,403 ) $ 4,665 Denominator: Weighted average common shares - Basic 32,085 31,398 32,021 31,346 Effective of dilutive shares: Share-based awards — 642 652 641 Convertible Notes — — 3,521 3,521 Weighted average common shares - Diluted 32,085 32,040 36,194 35,508 Net income per share attributable to common shareholders - Basic $ (0.54 ) $ 0.08 $ 0.06 $ 0.18 Net income per share attributable to common shareholders - Diluted $ (0.54 ) $ 0.08 $ (0.26 ) $ 0.13 * For the three months ended June 30, 2016 and 2015, the Convertible Notes would have been anti-dilutive if converted at the beginning of the respective periods and therefore, amounts are not applicable. For the periods presented, no tax benefits have been assumed in the weighted average share calculation due to a full valuation allowance on the Company's deferred tax assets. The following table represents the securities that could potentially dilute net income per share attributable to common shareholders in the future that were not included in the computation of diluted net income per share attributable to common shareholders because to do so would have been anti-dilutive for the periods presented: Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 Convertible Notes and share-based awards 4,146,517 3,725,326 18,798 174,485

GOODWILL AND OTHER INTANGIBLES

GOODWILL AND OTHER INTANGIBLES	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLES	GOODWILL AND OTHER INTANGIBLES As of June 30, 2016 and December 31, 2015 , the Company had the following acquired intangible assets: June 30, 2016 December 31, 2015 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (amounts in thousands) Intangible assets subject to amortization: Databases $ 31,225 $ 15,148 $ 16,077 $ 31,225 $ 14,150 $ 17,075 Customer relationships 41,212 22,382 18,830 47,204 20,734 26,470 Non-compete agreements 3,603 3,506 97 3,603 3,486 117 Trade names, definite-lived 3,200 196 3,004 3,200 49 3,151 $ 79,240 $ 41,232 $ 38,008 $ 85,232 $ 38,419 $ 46,813 Intangible assets not subject to amortization: Goodwill $ 77,376 $ 95,096 Trade names 35,502 36,101 $ 112,878 $ 131,197 As of June 30, 2016 , estimated annual amortization expense for continuing operations is as follows: Through Year Ending December 31: (amounts in thousands) 2016 $ 2,087 2017 4,140 2018 4,055 2019 4,019 2020 3,914 Thereafter 19,793 $ 38,008 The changes in the carrying amount of goodwill by segment are as follows: Nurse Physician Other Human Total (amounts in thousands) Balances as of December 31, 2015 Aggregate goodwill acquired $ 302,005 $ 43,405 $ 19,307 $ 364,717 Sale of CCE — — (9,889 ) (9,889 ) Accumulated impairment loss (259,732 ) — — (259,732 ) Goodwill, net of impairment loss 42,273 43,405 9,418 95,096 Changes to aggregate goodwill in 2016 Impairment charges — (17,720 ) — (17,720 ) Balances as of June 30, 2016 Aggregate goodwill acquired 302,005 43,405 19,307 364,717 Sale of CCE — — (9,889 ) (9,889 ) Accumulated impairment loss (259,732 ) (17,720 ) — (277,452 ) Goodwill, net of impairment loss $ 42,273 $ 25,685 $ 9,418 $ 77,376 During the three and six months ended June 30, 2016, total impairment charges on the condensed consolidated statement of operations were $24.3 million and entirely related to the Physician Staffing reporting unit. The impairment charges included $17.7 million related to goodwill, $0.6 million related to trade names, and $6.0 million related to customer relationships. In the second quarter of 2016, the Physician Staffing reporting unit continued to under-perform relative to management’s expectations. The lower than expected revenue was driven by lower booking volumes partly due to the loss of customers, and margins that were negatively impacted from continued investments in the business all through the first half of 2016. The Company considered these factors to be impairment indicators that warranted impairment testing of goodwill and other intangible assets as described below. 2016 Goodwill Impairment To determine the fair value of the Physician Staffing reporting unit, the Company used a combination of an income and a market approach to calculate the fair value of the Physician Staffing reporting unit. The discounted cash flow that served as the primary basis for the income approach was based on the Company’s discrete financial forecast of revenue, gross profit margins, operating costs and cash flows. It also considered historical and estimated future results, general economic and market conditions, as well as the impact of planned business and operational strategies. The assumptions used in the income approach included a discount rate of 11.5% and a terminal value growth rate of 3.0% for cash flows beyond the discrete forecast period of ten years . Assumptions used in the market approach included valuation multiples based on an analysis of multiples for comparable public companies. The Company utilized total enterprise value/Earnings before Interest Taxes Depreciation and Amortization (EBITDA) ranging from 7.5 to 8.5 . A 50% weighting was applied to the components of each approach to estimate the total fair value of goodwill. This weight is an estimate by management and was developed based on the specific characteristics, risks and uncertainties of the Physician Staffing reporting unit. As a result of the testing, the Company compared the implied fair value of goodwill to its carrying amount and recorded a non-cash pre tax goodwill impairment charge of $17.7 million . 2016 Other Intangible Asset Impairment Trade Names The Company valued the Physician Staffing trade names based on a Relief From Royalty methodology using projected cash flows of an estimated royalty fee. The royalty rate was determined by a blended rate using the Market Royalty Rate Method and the Apportionment of Profit Method. The calculated value of the trade names was compared to its carrying amount and, as a result, the Company recorded a non-cash pre tax impairment charge of $0.6 million . Customer Relationships The Company valued the Physician Staffing customer relationships based on the Multi-Period Excess Earnings Method (MPEEM). The MPEEM estimates the fair value based on the present value of the allocated future economic benefits. The inputs include the projected revenue and associated expenses from the customers, an estimated attrition rate, and a discount rate of 13.5% . The Company performed a recoverability test on the asset group which customers are a part of and deemed customer relationships to be impaired. As a result, the calculated value of customer relationships was compared to its carrying amount and the Company recorded a non-cash pre tax impairment charge of $6.0 million . The Company based its fair value estimates on assumptions it believed to be reasonable, but such assumptions are subject to inherent uncertainty. Actual results may differ from those estimates. See Note 9 - Fair Value Measurements.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
DEBT	DEBT At June 30, 2016 and December 31, 2015 , long-term debt consists of the following: June 30, 2016 December 31, 2015 Principal Unamortized Discount and Debt Issuance Costs Principal Unamortized Discount and Debt Issuance Costs (amounts in thousands) Term Loan, interest 2.71% at June 30, 2016 $ 40,000 $ (406 ) $ — $ — Senior Secured Asset-Based, weighted average interest 2.41% at December 31, 2015 — — 8,000 — Second Lien Term Loan, interest 5.75% at December 31, 2015 — — 30,000 (1,052 ) Convertible Notes, fixed rate interest of 8.00% 25,000 (5,342 ) 25,000 (6,007 ) Convertible Notes derivative liability 20,472 — 33,337 — Capital lease obligations 47 — 94 — Total debt 85,519 (5,748 ) 96,431 (7,059 ) Less current portion (2,033 ) — (8,071 ) — Long-term debt $ 83,486 $ (5,748 ) $ 88,360 $ (7,059 ) As of June 30, 2016 , the aggregate scheduled maturities of debt are as follows: Term Loan Convertible Notes Capital Leases (amounts in thousands) Through Years Ending December 31: 2016 $ 1,000 $ — $ 24 2017 2,500 — 13 2018 3,000 — 8 2019 3,500 — 2 2020 4,000 25,000 — Thereafter 26,000 — — Total $ 40,000 $ 25,000 $ 47 At December 31, 2015, the Company had a senior secured asset-based revolving credit facility ("First Lien Loan"), with a termination date of June 30, 2017, in the aggregate principal amount of up to $85.0 million , which included a subfacility for swingline loans up to an amount equal to 10% of the aggregate Revolver Commitments, as defined in the agreement, and a $35.0 million subfacility for standby letters of credit. The Company also had a five -year second lien term loan facility ("Second Lien Term Loan") in an aggregate principal amount of $30.0 million . The Company had the ability, at its option at any time, to prepay the Second Lien Term Loan in whole or in part at the redemption prices set forth therein, which range from 103% of the principal amount thereof for prepayments during the period July 1, 2015 through June 30, 2016, 102% of the principal amount thereof for prepayments during the period July 1, 2016 through June 30, 2017, and 100% of the principal amount thereof for prepayments after June 30, 2017. 2016 Senior Credit Facilities On June 22, 2016, the Company entered into a senior credit agreement (“Credit Agreement”), which provides a term loan of $40.0 million ("Term Loan") and a revolving credit facility of up to $100.0 million ("Revolving Credit Facility") (together with the Term Loan, the "Senior Credit Facilities") both of which mature in five years. The Revolving Credit Facility includes a subfacility for swingline loans up to an amount not to exceed $15.0 million , and a $35.0 million sublimit for the issuance of standby letters of credit. The Credit Agreement also includes a provision permitting the Company, subject to certain conditions, to increase the aggregate amount of the commitments under the Revolving Credit Facility or establish one or more additional term loans in an aggregate amount of up to $50.0 million with optional additional commitments from existing lenders or new commitments from additional lenders. The Term Loan is payable in quarterly installments, with the first payment due September 30, 2016, and each such installment being in the aggregate principal amount (subject to adjustment as a result of prepayments) equal to 1.25% of the principal amount for the first four installments, 1.875% for the next eight installments and 2.50% of the principal amount for the remaining installments. Proceeds of the Senior Credit Facilities were used primarily to refinance the Company’s First Lien Loan and Second Lien Term Loan and to pay related transaction fees and expenses, including a prepayment penalty of $0.6 million . In addition, as of June 22, 2016, $23.1 million of standby letters of credit issued under the First Lien Loan have been rolled into and been deemed issued under the Revolving Credit Facility. The Revolving Credit Facility can be used to provide ongoing working capital, fund permitted acquisitions and for other general corporate purposes of the Company and its subsidiaries. The repayment of the Second Lien Term Loan was treated as extinguishment of debt and, as a result, the Company recognized a loss on extinguishment of debt of approximately $1.6 million in the second quarter of 2016, related to the write-off of unamortized net debt discount and issuance costs as well as transaction fees and expenses. Subject to the Credit Agreement, the Company pays interest on (i) each Base Rate Loan at the Base Rate (as defined therein) plus the Applicable Margin in effect from time to time, (ii) each LIBOR Index Rate Loan at the One Month LIBOR Index Rate (as defined therein) plus the Applicable Margin in effect from time to time and (iii) each Eurodollar Loan at the Adjusted LIBOR for the applicable Interest Period (as defined therein) in effect for such Loan plus the Applicable Margin in effect from time to time. The Applicable Margin, as of any date, is a percentage per annum determined by reference to the applicable Consolidated Net Leverage Ratio (as defined by the agreement) in effect on such date as set forth in the table below. Level Consolidated Net Leverage Ratio Eurodollar Loans, LIBOR Index Rate Loans and Letter of Credit Fee Base Rate Loans Commitment Fee I Less than 1.50:1.00 1.75% 0.75% 0.25% II Greater than or equal to 1.50:1.00 2.00% 1.00% 0.30% III Greater than or equal to 2.00:1.00 2.25% 1.25% 0.30% IV Greater than or equal to 2.50:1.00 2.50% 1.50% 0.35% V Greater than or equal to 3.00:1.00 2.75% 1.75% 0.40% As of June 30, 2016 , the Term Loan and Revolving Credit Facility bore interest at a rate equal to One Month LIBOR plus 225 basis points. The interest rate is subject to an increase of 200 basis points if an event of default exists under the Credit Agreement. The Company is required to pay a commitment fee on the average daily unused portion of the Revolving Credit Facility, based on the Applicable Margin which, as of June 30, 2016 , was 0.30% . The Company has the right at any time and from time to time to prepay any borrowing, in whole or in part, without premium or penalty, by giving irrevocable written notice (or telephonic notice promptly confirmed in writing) except that such notice shall be revocable if a prepayment is being made in anticipation of concluding a financing arrangement, and the Company is ultimately unable to secure such financing arrangement. The Company is required to prepay the Senior Credit Facilities under certain circumstances including from net cash proceeds from asset sales or dispositions in excess of certain thresholds, as well as from net cash proceeds from the issuance of certain debt by the Company. The Credit Agreement contains customary representations, warranties, and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to some exceptions, on (i) indebtedness and preferred equity, (ii) liens, (iii) fundamental changes, (iv) investments, (v) restricted payments, and (vi) sale of assets and certain other restrictive agreements. The Credit Agreement also contains customary events of default, such as payment defaults, cross-defaults to other material indebtedness, bankruptcy and insolvency, the occurrence of a defined change in control and the failure to observe the negative covenants and other covenants related to the operation of the Company’s business. The Credit Agreement also includes two financial covenants, commencing with the fiscal quarter ending September 30, 2016: (i) limiting the Company’s maximum Consolidated Total Leverage ratio (as defined therein) to be no greater than 3.50 :1.00 for the fiscal quarters ending September 30, 2016 through June 30, 2017, 3.25 :1.00 for the fiscal quarters ending September 30, 2017 through June 30, 2018, and 3.00 :1.00 for each fiscal quarter ending thereafter and as adjusted pursuant to a Qualified Permitted Acquisition (as defined therein); and, (ii) requiring a minimum Consolidated Fixed Charge Coverage ratio (as defined therein) as of the end of each fiscal quarter of 1.50 :1.00. The obligations under the Credit Agreement are guaranteed by all of the Company’s domestic wholly-owned subsidiaries. The obligations under the Credit Agreement are secured by a first-priority security interest in the Collateral (as defined therein). As of June 30, 2016 , the Company had $23.1 million letters of credit outstanding and $76.9 million available under the Revolving Credit Facility. The letters of credit relate to the Company’s workers’ compensation and professional liability insurance policies. Convertible Notes As of June 30, 2016 , the Convertible Notes are convertible at the option of the holders thereof at any time into shares of the Company’s common stock, par value $0.0001 per share (Common Stock), at an initial conversion price of $7.10 per share, or 3,521,126 shares of Common Stock. After three years from the issuance date, the Company has the right to force a conversion of the Convertible Notes if the volume-weighted average price (VWAP) per share of its Common Stock exceeds 125% of the then conversion price for 20 days of a 30 day trading period. The conversion price is subject to adjustment pursuant to customary weighted average anti-dilution provisions including adjustments for the following: Common Stock dividends or distributions; issuance of any rights, warrants of options to acquire Common Stock; distributions of property; tender offer or exchange offer payments; cash dividends; or certain issuances of Common Stock at less than the conversion price. Upon conversion of the Convertible Notes, the Company will exchange, for the applicable conversion amount thereof a number of shares of Common Stock, with no maximum, on amount, equal to the amount determined by dividing (i) such conversion amount by (ii) the conversion price in effect at the time of conversion. No fractional shares of Common Stock will be issued upon conversion of the Conversion Notes. In lieu of fractional shares, the Company shall pay cash in respect of each fractional share multiplied by the 30-day VWAP as of the closing of business on the Business Day immediately preceding the conversion date as well as any unpaid accrued interest. The Convertible Notes bear interest at a rate of 8.00% per annum, payable in quarterly cash installments; provided, however, that, at the Company’s option, up to 4.00% of the interest payable may be “paid-in-kind” through a quarterly addition of such “paid-in-kind” interest amount to the principal amount of the Convertible Notes. The Convertible Notes will mature on June 30, 2020, unless earlier repurchased, redeemed or converted. Subject to certain exceptions, the Company is not permitted to redeem the Convertible Notes until June 30, 2017. If the Company redeems the Convertible Notes on or after June 30, 2017, the Company is required to pay a premium of 15% of the amount of principal of the Convertible Notes redeemed. If the Convertible Notes are redeemed prior to June 30, 2017, pursuant to a Prohibited Transaction, as defined by the agreement, the Company is required to pay a premium equal to the greater of (i) the sum of (a) the amount of principal of the Convertible Notes redeemed, plus (b) the accrued but unpaid interests on the principal amount so redeemed to the date of the redemption, plus (c) a “make whole” amount (described below) and (ii) the sum of (x) the average 30-day VWAP per share of Common Stock multiplied by the number of shares of Common Stock that the redeemed Convertible Notes are then convertible into, with no maximum, and (y) the accrued but unpaid interest on the Convertible Notes. The “make whole” amount is equal to the excess, if any, of (1) the present value at the date of redemption of (A) 115% of the principal amount of the Convertible Notes redeemed, plus (B) all remaining scheduled interest due on the principal amount of the notes being redeemed through June 30, 2017 computed using a discount rate equal to the Treasury rate as of the date of redemption plus 50 basis points over (2) the outstanding principal amount of the Convertible Notes then redeemed.

CONVERTIBLE NOTES DERIVATIVE LI

CONVERTIBLE NOTES DERIVATIVE LIABILITY	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
CONVERTIBLE NOTES DERIVATIVE LIABILITY	CONVERTIBLE NOTES DERIVATIVE LIABILITY Derivative financial instruments, as defined in ASC 815, Accounting for Derivative Financial Instruments and Hedging Activities , consist of financial instruments or other contracts that contain a notional amount and one or more underlyings (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company issued Convertible Notes with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in the financial statements. The Convertible Notes are subject to anti-dilution adjustments that allow for the reduction in the Conversion Price, as defined in the agreement, in the event the Company subsequently issues equity securities including Common Stock or any security convertible or exchangeable for shares of Common Stock for a price less than the current conversion price. In addition, the Convertible Notes allow the issuer to exercise optional redemption features and the holder to exercise an offer to purchase feature, under certain conditions. The Company accounted for the conversion option in accordance with ASC 815. Since this conversion feature is not considered to be solely indexed to the Company’s own stock the derivative was recorded as a liability in the line item long-term debt on the Company's condensed consolidated balance sheets. See Note 7 - Debt. The Company’s Convertible Notes derivative liability is measured at fair value using a trinomial lattice model. The optional redemption features, along with the offer to purchase features are incorporated into the valuation model. Inputs into the model require estimates, including such items as estimated volatility of the Company's stock, estimated credit risk of the Company, estimated probabilities of change of control and issuance of additional financing, risk-free interest rate, and the estimated life of the financial instruments being fair valued. In addition, since the conversion price contains an anti-dilution adjustment, the probability that the Conversion Price of the Notes would decrease as the share price decreased is incorporated into the valuation calculation. The inputs into the valuation model are as follows: June 30, 2016 Closing share price $13.92 Conversion price $7.10 Risk-free rate 0.91% Expected volatility 40% Dividend yield —% Expected life 4.00 The fair value of this derivative liability is primarily determined by fluctuations in our stock price. In addition, changes in our credit risk profile impact the fair value determination. As of June 30, 2016 , a $1 increase or decrease in our stock price would result in a corresponding increase or decrease of approximately $3.3 million in the fair value of the derivative liability, and a 1% increase or decrease in interest rates would result in a corresponding increase or decrease of $0.8 million in the fair value of the derivative liability. These fluctuations result in a current period gain or loss that is presented on the condensed consolidated statements of operations as loss (gain) on derivative liability.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Fair Value Measurements and Disclosures Topic of the FASB ASC defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Fair Value Measurements and Disclosures Topic also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 —Quoted prices in active markets for identical assets or liabilities. Level 2 —Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Items Measured at Fair Value on a Recurring Basis At June 30, 2016 and December 31, 2015 , the Company’s financial assets/liabilities required to be measured on a recurring basis were: contingent consideration receivable, deferred compensation liability included in other long-term liabilities, convertible notes derivative liability included in long-term debt and capital lease obligations, and contingent purchase price liabilities included in deferred purchase price on the condensed consolidated balance sheets. Contingent consideration receivable —In connection with the sale of its education seminars business, Cross Country Education, LLC ("CCE"), the Company treated a related performance-based earnout as a contingent consideration receivable at December 31, 2015 for accounting purposes. The Company assigned no fair value to this earnout as of December 31, 2015 as the performance milestones were not met. The amount escrowed for this earnout was released to the buyer in the first quarter of 2016. Deferred compensation —The Company utilizes Level 1 inputs to value its deferred compensation liability. The Company’s deferred compensation liability is measured using publicly available indices that define the liability amounts, as per the plan documents. Convertible Notes derivative liability —The Company utilizes Level 3 inputs to value its convertible notes derivative liability. See Note 8 - Convertible Notes Derivative Liability. Contingent purchase price liabilities —Potential earnout payments related to the acquisition of Mediscan are contingent upon meeting certain performance requirements through 2019. See Note 3 - Acquisitions. The long-term portion of these liabilities is included in contingent consideration, and the short-term portion is included in other current liabilities on the condensed consolidated balance sheets. The Company utilized Level 3 inputs to value these contingent purchase price liabilities as significant unobservable inputs were used in the calculation of their fair value. Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model in a Monte Carlo simulation setting, utilizing significant unobservable inputs, including the expected volatility of Mediscan gross profits and an estimated discount rate commensurate with the risks of the expected gross profit stream. Significant increases (decreases) in the volatility, or decreases (increases) in the discount rate would result in a significantly higher (lower) fair value, respectively, and commensurate changes to these liabilities. The fair value of contingent consideration and the associated liabilities will be adjusted to fair value at each reporting date until actual settlement occurs, with the changes in fair value and liability accretion reflected as acquisition-related contingent consideration on the condensed consolidated statements of operations. The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis as of June 30, 2016 and December 31, 2015 : Fair Value Measurements June 30, 2016 December 31, 2015 Financial Liabilities: (amounts in thousands) (Level 1) Deferred compensation $ 1,362 $ 1,412 (Level 3) Convertible Notes derivative liability $ 20,472 $ 33,337 Contingent purchase price liabilities $ 4,139 $ 3,686 The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy: Contingent Purchase Convertible Notes Price Liabilities (a) Derivative Liability (amounts in thousands) December 31, 2015 $ 3,686 $ 33,337 Payments (17 ) — Accretion expense 287 — Valuation gain for the period — (16,436 ) March 31, 2016 3,956 16,901 Accretion expense 183 — Valuation loss for the period — 3,571 June 30, 2016 $ 4,139 $ 20,472 _______________ (a) Related to the Mediscan acquisition on October 30, 2015. See Note 3 - Acquisitions. The key assumptions used to calculate the fair value of contingent consideration at the acquisition date remained consistent at June 30, 2016 . Accretion expense is included as acquisition-related contingent consideration on the condensed consolidated statement of operations. Should the assumptions regarding probability of achievement of certain targets change in future periods, the change in fair value of the contingent consideration will be recognized, along with accretion expense, as acquisition-related contingent consideration. Items Measured at Fair Value on a Non-Recurring Basis Goodwill, trade names, and other identifiable intangible assets are reviewed for impairment annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If the testing performed indicates that impairment has occurred, the Company records a non-cash impairment charge for the difference between the carrying amount of the goodwill or other intangible assets and the implied fair value of the goodwill or other intangible assets in the period the determination is made. The Company recorded total pre tax non-cash impairment charges of $24.3 million ( $17.3 million after tax) related to its Physician Staffing reporting unit. See Note 6 - Goodwill and Other Intangibles for more information about the fair value measurements and related inputs. The table below presents the fair value of the Physician Staffing goodwill and intangible assets required to be measured at fair value as of June 30, 2016 . Fair Value Measurements June 30, 2016 (amounts in thousands) (Level 3) Goodwill $ 25,685 Trade names $ 15,000 Customer relationships $ 1,300 Other Fair Value Disclosures Financial instruments not measured or recorded at fair value in the accompanying condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and short and long-term debt. The estimated fair value of accounts receivable, accounts payable and accrued expenses approximate their carrying amount due to the short-term nature of these instruments. The estimated fair value of the Company's debt was calculated using a discounted cash flow analysis and appropriate valuation methodologies using Level 2 inputs from available market information. The estimated fair value of the Company's new term loan facility approximates principal amount due to the short time span since the Company entered into the new Credit Agreement. The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value: June 30, 2016 December 31, 2015 Carrying Fair Carrying Fair Financial Liabilities: (amounts in thousands) (Level 2) Second Lien Term Loan, net $ — $ — $ 28,948 $ 30,600 Term Loan, net $ 39,593 $ 39,593 $ — $ — Convertible Notes, net $ 19,658 $ 28,500 $ 18,993 $ 23,250 Senior Secured Asset-Based Loan $ — $ — $ 8,000 $ 8,000 Concentration of Risk The Company has invested its excess cash in highly-rated overnight funds and other highly-rated liquid accounts. The Company has been exposed to credit risk associated with these investments. The Company minimizes its credit risk relating to these positions by monitoring the financial condition of the financial institutions involved and by primarily conducting business with large, well established financial institutions and diversifying its counterparties. The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts represents the Company’s estimate of uncollectible receivables based on a review of specific accounts and the Company’s historical collection experience. The Company writes off specific accounts based on an ongoing review of collectability as well as past experience with the customer. The Company’s contract terms typically require payment between 15 to 60 days from the date services are provided and are considered past due based on the particular negotiated contract terms. Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock Repurchase Program During the six months ended June 30, 2016 and 2015 , the Company did not repurchase any shares of its Common Stock under its February 2008 Board authorization. As of June 30, 2016 , the Company may purchase up to an additional 942,443 shares of Common Stock under the February 2008 Board authorization, subject to certain conditions in the Company's new Credit Agreement. The Company may repurchase up to an aggregate amount not to exceed $2.5 million in any fiscal year, or an unlimited amount if the Company meets certain conditions as described in its new Credit Agreement. At June 30, 2016 , the Company had 32,198,575 shares of Common Stock outstanding. Share-Based Payments During the six months ended June 30, 2016 , 246,020 of restricted stock awards and 202,442 of performance stock awards were granted under the 2014 Omnibus Incentive Plan (2014 Plan) to the Company's non-employee Directors and management team. Pursuant to the 2014 Plan, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. If the minimum level of performance is attained for the 2016 awards, restricted stock will be issued with a vesting date of December 31, 2018, subject to the employee’s continuing employment. During the first quarter of 2016, the Company's Compensation Committee of the Board of Directors approved a 100% level of attainment for the 2015 performance-based share awards, resulting in the issuance of 148,178 performance shares that will vest on December 31, 2017. The following table summarizes restricted stock awards and performance stock awards activity issued under the 2014 Plan for the six months ended June 30, 2016 : Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2016 586,488 $ 7.82 234,138 $ 9.81 Granted 246,020 $ 12.01 202,442 $ 11.63 Vested (259,951 ) $ 7.06 — $ — Forfeited (12,667 ) $ 10.85 (9,334 ) $ 11.79 Unvested restricted stock awards, June 30, 2016 559,890 $ 9.95 427,246 $ 10.63 During the three and six months ended June 30, 2016 , $1.1 million and $1.8 million , respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 164,274 and 215,365 shares, respectively, of Common Stock were issued upon the vesting of restricted stock. During the three and six months ended June 30, 2015 , $0.8 million and $1.2 million , respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 165,842 and 180,301 shares, respectively, of Common Stock were issued upon the vesting of restricted stock.

SEGMENT DATA

SEGMENT DATA	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
SEGMENT DATA	SEGMENT DATA In accordance with the Segment Reporting Topic of the FASB ASC, the Company reports three business segments – Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. The Company manages and segments its business based on the services it offers to its customers as described below: ● Nurse and Allied Staffing – Nurse and Allied Staffing provides traditional staffing, including temporary and permanent placement of travel nurses and allied professionals and branch-based local nurses and allied staffing. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, retailers, and many other healthcare providers throughout the U.S. The results of the Mediscan acquisition have been aggregated with the Company's Nurse and Allied Staffing business segment. See Note 3 - Acquisitions. ● Physician Staffing – Physician Staffing provides physicians in many specialties, certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) as independent contractors on temporary assignments throughout the U.S. at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. ● Other Human Capital Management Services – Subsequent to the sale of CCE on August 31, 2015, Other Human Capital Management Services includes retained and contingent search services for physicians, healthcare executives and other healthcare professionals within the U.S. The Company’s management evaluates performance of each segment primarily based on revenue and contribution income. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments’ internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows: Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 (amounts in thousands) Revenues: Nurse and Allied Staffing $ 172,048 $ 152,677 $ 340,813 $ 301,789 Physician Staffing 23,927 29,794 48,380 57,141 Other Human Capital Management Services 3,468 10,146 6,833 19,651 $ 199,443 $ 192,617 $ 396,026 $ 378,581 Contribution income: (a) Nurse and Allied Staffing (b) $ 17,615 $ 12,821 $ 34,405 $ 23,723 Physician Staffing 2,050 2,228 3,603 4,344 Other Human Capital Management Services 69 747 (42 ) 1,349 19,734 15,796 37,966 29,416 Unallocated corporate overhead (b) 9,791 8,455 20,159 16,295 Depreciation 1,059 989 2,064 1,949 Amortization 1,406 983 2,813 1,965 Acquisition and integration costs — 40 — 158 Acquisition-related contingent consideration 183 — 470 — Restructuring costs — 1,007 — 1,007 Impairment charges 24,311 — 24,311 — (Loss) income from operations $ (17,016 ) $ 4,322 $ (11,851 ) $ 8,042 _______________ (a) The Company defines contribution income as income or loss from operations before depreciation, amortization, acquisition and integration costs, acquisition-related contingent consideration, restructuring costs, impairment charges and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance and is provided in accordance with ASC 280, Segment Reporting Topic of the FASB ASC. (b) For the three and six months ended June 30, 2015 , $0.3 million and $0.6 million , respectively, of expenses was reclassified from Nurse and Allied Staffing to unallocated corporate overhead to conform to the current period presentation.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Commitments The Company has entered into non-cancelable operating lease agreements for the rental of office space and equipment. Certain of these leases include options to renew as well as rent escalation clauses and in certain cases, incentives from the landlord for rent-free months and premises reductions, and allowances for tenant improvements. The rent escalations and incentives have been reflected in the table below. Future minimum lease payments, as of June 30, 2016 , associated with these agreements with terms of one year or more are as follows: Through Year Ending December 31: (amounts in thousands) 2016 $ 3,657 2017 6,541 2018 5,569 2019 4,365 2020 3,879 Thereafter 15,489 $ 39,500 Legal Contingencies The Company is subject to legal proceedings and claims that arise in the ordinary course of its business. The Company does not believe the outcome of these matters will have a material adverse effect on the Company's business, financial condition, results of operations or cash flows. Sales and Other State Non-Income Tax Liabilities The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses on its condensed consolidated statements of operations and the liability is reflected in sales tax payable within other current liabilities as of December 31, 2015 and June 30, 2016 , on its condensed consolidated balance sheets.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the periods ended June 30, 2016 and 2015 , the Company has calculated its effective tax rate based on year-to-date results (under ASC 740-270-30-18) as opposed to estimating its annual effective tax rate. The Company’s effective tax rate for the three and six months ended June 30, 2016 was 28.0% and 155.8% , respectively, including the impact of discrete items. Excluding discrete items, the Company’s effective tax rate for the three and six months ended June 30, 2016 was 27.2% and 151.3% , respectively. The effective tax rates are different than the statutory rates primarily due to the impact from amortization of indefinite-lived intangible assets for tax purposes, the partial non-deductibility of certain per diem expenses and international and state minimum taxes. The Company records valuation allowances to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment, including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support its reversal. As of June 30, 2016 , the Company had approximately $0.9 million of unrecognized tax benefits included in other current liabilities and other long-term liabilities ( $4.3 million , net of deferred taxes, which would affect the effective tax rate if recognized). During the six months ended June 30, 2016 , the Company had gross increases of $0.5 million to its current year unrecognized tax benefits related to federal and state tax issues. The tax years of 2004, 2005, 2008, and 2010 through 2015 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services to hospitals which are affiliated with certain members of the Company’s Board of Directors. Management believes services with related parties were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was $1.3 million and $2.7 million for the three and six months ended June 30, 2016 , respectively. Revenue related to these transactions was $4.0 million and $7.0 million for the three and six months ended June 30, 2015 , respectively. Accounts receivable due from these hospitals at both June 30, 2016 and December 31, 2015 were approximately $0.6 million . In connection with the acquisition of MSN, the Company acquired a 68% ownership interest in InteliStaf of Oklahoma, LLC, a joint venture between the Company and a hospital system. The Company generated revenue providing staffing services to the hospital system of $2.9 million and $6.0 million for the three and six months ended June 30, 2016 , respectively, and $2.2 million and $4.3 million for the three and six months ended June 30, 2015 , respectively. At June 30, 2016 and December 31, 2015 , the Company had a receivable balance of $1.5 million and $1.4 million , respectively, and a payable balance of $0.1 million and $0.2 million , respectively, relating to these staffing services. Subsequent to the Company's acquisition of Mediscan on October 30, 2015, Mediscan continued to operate at premises owned, in part, by the founding members of Mediscan. The Company paid $0.1 million and $0.2 million in rent expense for these premises for the three and six months ended June 30, 2016 , respectively.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. There are various methods of adoption for each aspect. The Company is currently evaluating the effect ASU 2016-09 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging: Contingent Put and Call Options in Debt Instruments , to clarify the steps required to assess whether a call or put option meets the criteria for bifurcation as an embedded derivative. ASU 2016-06 is effective for interim and annual periods beginning after December 15, 2016, and requires a modified retrospective approach to adoption. Early adoption is permitted. The Company is currently evaluating the effect ASU 2016-06 will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is currently evaluating the effect ASU 2016-02 will have on its consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In March 2016, the FASB issued ASU 2016-08 which further clarifies the guidance on the principal versus agent considerations within ASU 2014-09. In April 2016, the FASB issued ASU 2016-10 to expand the guidance on identifying performance obligations and licensing within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12 to improve revenue recognition in the areas of collectability, presentation of sales tax and other similar taxes collected from customers, non-cash consideration, contract modifications and completed contracts at transition. This update also amends the disclosure requirements within ASU 2014-09 for entities that retrospectively apply the guidance. The latest amendments are intended to address implementation issues that were raised by stakeholders and discussed by the Revenue Recognition Transition Resource Group, and provide additional practical expedients. These standards are effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the new guidance to determine the impact, if any, it will have on its consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 . These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The December 31, 2015 condensed consolidated balance sheet included herein was derived from the December 31, 2015 audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K. Certain prior period amounts have been reclassified to conform to the current period presentation. See Note 11 - Segment Data.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, the valuation of accounts receivable, goodwill and intangible assets, other long-lived assets, share-based compensation, accruals for health, workers’ compensation and professional liability claims, valuation of deferred tax assets and the purchase price allocation, derivative liability, legal contingencies, future contingent considerations, income taxes and sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In September 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Prior to the issuance of the ASU, entities were required to retrospectively apply adjustments made to provisional amounts recognized in a business combination. The Company adopted this guidance in the first quarter of 2016, with no impact on its financial position and results of operations upon adoption. This new guidance may impact the Company for potential measurement adjustments related to its 2015 acquisition. See Note 3 - Acquisitions. In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40), Customers Accounting for Fees Paid in a Cloud Computing Arrangement , to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license element, then the customer should account for the software license element arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company prospectively adopted this guidance in the first quarter of 2016, with no impact on adoption. In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs . This guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The Company adopted this guidance in the first quarter of 2016, and reclassified $0.5 million of the Company's net debt issuance costs to long-term debt and capital lease obligations in its condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015 . In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. There are various methods of adoption for each aspect. The Company is currently evaluating the effect ASU 2016-09 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging: Contingent Put and Call Options in Debt Instruments , to clarify the steps required to assess whether a call or put option meets the criteria for bifurcation as an embedded derivative. ASU 2016-06 is effective for interim and annual periods beginning after December 15, 2016, and requires a modified retrospective approach to adoption. Early adoption is permitted. The Company is currently evaluating the effect ASU 2016-06 will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is currently evaluating the effect ASU 2016-02 will have on its consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In March 2016, the FASB issued ASU 2016-08 which further clarifies the guidance on the principal versus agent considerations within ASU 2014-09. In April 2016, the FASB issued ASU 2016-10 to expand the guidance on identifying performance obligations and licensing within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12 to improve revenue recognition in the areas of collectability, presentation of sales tax and other similar taxes collected from customers, non-cash consideration, contract modifications and completed contracts at transition. This update also amends the disclosure requirements within ASU 2014-09 for entities that retrospectively apply the guidance. The latest amendments are intended to address implementation issues that were raised by stakeholders and discussed by the Revenue Recognition Transition Resource Group, and provide additional practical expedients. These standards are effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the new guidance to determine the impact, if any, it will have on its consolidated financial statements.

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Schedule of unaudited pro forma financial information	The following unaudited pro forma financial information approximates the consolidated results of operations of the Company as if the Mediscan acquisition had occurred as of January 1, 2015, after giving effect to certain adjustments, including additional interest expense on the amount the Company borrowed on the date of the transaction, the amortization of acquired intangible assets, and the elimination of certain expenses that will not be recurring in post-acquisition periods, net of an estimated income tax impact. These results are not necessarily indicative of future results as they do not include incremental investments in support functions, elimination of costs for integration or operating synergies or an estimate of any impact on interest expense resulting from the operating cash flow of the acquired business, among other adjustments that could be made in the future but are not factually supportable on the date of the transaction. Six Months Ended June 30, 2015 (unaudited, amounts in thousands) Revenue from services $ 399,389 Net income attributable to common shareholders $ 6,629 Net income per share attributable to common shareholders - Basic $ 0.21 Net income per share attributable to common shareholders - Diluted $ 0.16

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share	The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 (amounts in thousands, except per share data) Numerator: Net income attributable to common shareholders - Basic $ (17,237 ) $ 2,573 $ 1,785 $ 5,507 Interest on Convertible Notes * * 1,677 1,667 Gain on derivative liability * * (12,865 ) (2,509 ) Net income attributable to common shareholders - Diluted $ (17,237 ) $ 2,573 $ (9,403 ) $ 4,665 Denominator: Weighted average common shares - Basic 32,085 31,398 32,021 31,346 Effective of dilutive shares: Share-based awards — 642 652 641 Convertible Notes — — 3,521 3,521 Weighted average common shares - Diluted 32,085 32,040 36,194 35,508 Net income per share attributable to common shareholders - Basic $ (0.54 ) $ 0.08 $ 0.06 $ 0.18 Net income per share attributable to common shareholders - Diluted $ (0.54 ) $ 0.08 $ (0.26 ) $ 0.13 * For the three months ended June 30, 2016 and 2015, the Convertible Notes would have been anti-dilutive if converted at the beginning of the respective periods and therefore, amounts are not applicable.
Schedule of Potentially Dilutive Securities	The following table represents the securities that could potentially dilute net income per share attributable to common shareholders in the future that were not included in the computation of diluted net income per share attributable to common shareholders because to do so would have been anti-dilutive for the periods presented: Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 Convertible Notes and share-based awards 4,146,517 3,725,326 18,798 174,485

GOODWILL AND OTHER INTANGIBLES

GOODWILL AND OTHER INTANGIBLES (Tables)	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Acquired Intangible Assets	As of June 30, 2016 and December 31, 2015 , the Company had the following acquired intangible assets: June 30, 2016 December 31, 2015 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (amounts in thousands) Intangible assets subject to amortization: Databases $ 31,225 $ 15,148 $ 16,077 $ 31,225 $ 14,150 $ 17,075 Customer relationships 41,212 22,382 18,830 47,204 20,734 26,470 Non-compete agreements 3,603 3,506 97 3,603 3,486 117 Trade names, definite-lived 3,200 196 3,004 3,200 49 3,151 $ 79,240 $ 41,232 $ 38,008 $ 85,232 $ 38,419 $ 46,813 Intangible assets not subject to amortization: Goodwill $ 77,376 $ 95,096 Trade names 35,502 36,101 $ 112,878 $ 131,197
Estimated Annual Amortization Expense	As of June 30, 2016 , estimated annual amortization expense for continuing operations is as follows: Through Year Ending December 31: (amounts in thousands) 2016 $ 2,087 2017 4,140 2018 4,055 2019 4,019 2020 3,914 Thereafter 19,793 $ 38,008
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill by segment are as follows: Nurse Physician Other Human Total (amounts in thousands) Balances as of December 31, 2015 Aggregate goodwill acquired $ 302,005 $ 43,405 $ 19,307 $ 364,717 Sale of CCE — — (9,889 ) (9,889 ) Accumulated impairment loss (259,732 ) — — (259,732 ) Goodwill, net of impairment loss 42,273 43,405 9,418 95,096 Changes to aggregate goodwill in 2016 Impairment charges — (17,720 ) — (17,720 ) Balances as of June 30, 2016 Aggregate goodwill acquired 302,005 43,405 19,307 364,717 Sale of CCE — — (9,889 ) (9,889 ) Accumulated impairment loss (259,732 ) (17,720 ) — (277,452 ) Goodwill, net of impairment loss $ 42,273 $ 25,685 $ 9,418 $ 77,376

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Long-term Debt	At June 30, 2016 and December 31, 2015 , long-term debt consists of the following: June 30, 2016 December 31, 2015 Principal Unamortized Discount and Debt Issuance Costs Principal Unamortized Discount and Debt Issuance Costs (amounts in thousands) Term Loan, interest 2.71% at June 30, 2016 $ 40,000 $ (406 ) $ — $ — Senior Secured Asset-Based, weighted average interest 2.41% at December 31, 2015 — — 8,000 — Second Lien Term Loan, interest 5.75% at December 31, 2015 — — 30,000 (1,052 ) Convertible Notes, fixed rate interest of 8.00% 25,000 (5,342 ) 25,000 (6,007 ) Convertible Notes derivative liability 20,472 — 33,337 — Capital lease obligations 47 — 94 — Total debt 85,519 (5,748 ) 96,431 (7,059 ) Less current portion (2,033 ) — (8,071 ) — Long-term debt $ 83,486 $ (5,748 ) $ 88,360 $ (7,059 ) Level Consolidated Net Leverage Ratio Eurodollar Loans, LIBOR Index Rate Loans and Letter of Credit Fee Base Rate Loans Commitment Fee I Less than 1.50:1.00 1.75% 0.75% 0.25% II Greater than or equal to 1.50:1.00 2.00% 1.00% 0.30% III Greater than or equal to 2.00:1.00 2.25% 1.25% 0.30% IV Greater than or equal to 2.50:1.00 2.50% 1.50% 0.35% V Greater than or equal to 3.00:1.00 2.75% 1.75% 0.40%
Aggregate scheduled maturities of debt	As of June 30, 2016 , the aggregate scheduled maturities of debt are as follows: Term Loan Convertible Notes Capital Leases (amounts in thousands) Through Years Ending December 31: 2016 $ 1,000 $ — $ 24 2017 2,500 — 13 2018 3,000 — 8 2019 3,500 — 2 2020 4,000 25,000 — Thereafter 26,000 — — Total $ 40,000 $ 25,000 $ 47

CONVERTIBLE NOTES DERIVATIVE 27

CONVERTIBLE NOTES DERIVATIVE LIABILITY (Tables)	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Inputs into Valuation Model	The inputs into the valuation model are as follows: June 30, 2016 Closing share price $13.92 Conversion price $7.10 Risk-free rate 0.91% Expected volatility 40% Dividend yield —% Expected life 4.00

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis	The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis as of June 30, 2016 and December 31, 2015 : Fair Value Measurements June 30, 2016 December 31, 2015 Financial Liabilities: (amounts in thousands) (Level 1) Deferred compensation $ 1,362 $ 1,412 (Level 3) Convertible Notes derivative liability $ 20,472 $ 33,337 Contingent purchase price liabilities $ 4,139 $ 3,686
Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3	The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy: Contingent Purchase Convertible Notes Price Liabilities (a) Derivative Liability (amounts in thousands) December 31, 2015 $ 3,686 $ 33,337 Payments (17 ) — Accretion expense 287 — Valuation gain for the period — (16,436 ) March 31, 2016 3,956 16,901 Accretion expense 183 — Valuation loss for the period — 3,571 June 30, 2016 $ 4,139 $ 20,472 _______________ (a) Related to the Mediscan acquisition on October 30, 2015. See Note 3 - Acquisitions. The key assumptions used to calculate the fair value of contingent consideration at the acquisition date remained consistent at June 30, 2016 . Accretion expense is included as acquisition-related contingent consideration on the condensed consolidated statement of operations. Should the assumptions regarding probability of achievement of certain targets change in future periods, the change in fair value of the contingent consideration will be recognized, along with accretion expense, as acquisition-related contingent consideration.
Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Non-Recurring Basis	The table below presents the fair value of the Physician Staffing goodwill and intangible assets required to be measured at fair value as of June 30, 2016 . Fair Value Measurements June 30, 2016 (amounts in thousands) (Level 3) Goodwill $ 25,685 Trade names $ 15,000 Customer relationships $ 1,300
Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value	The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value: June 30, 2016 December 31, 2015 Carrying Fair Carrying Fair Financial Liabilities: (amounts in thousands) (Level 2) Second Lien Term Loan, net $ — $ — $ 28,948 $ 30,600 Term Loan, net $ 39,593 $ 39,593 $ — $ — Convertible Notes, net $ 19,658 $ 28,500 $ 18,993 $ 23,250 Senior Secured Asset-Based Loan $ — $ — $ 8,000 $ 8,000

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Summary of Restricted Stock Activity	The following table summarizes restricted stock awards and performance stock awards activity issued under the 2014 Plan for the six months ended June 30, 2016 : Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2016 586,488 $ 7.82 234,138 $ 9.81 Granted 246,020 $ 12.01 202,442 $ 11.63 Vested (259,951 ) $ 7.06 — $ — Forfeited (12,667 ) $ 10.85 (9,334 ) $ 11.79 Unvested restricted stock awards, June 30, 2016 559,890 $ 9.95 427,246 $ 10.63

SEGMENT DATA (Tables)

SEGMENT DATA (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Information on Operating Segments and Reconciliation to Loss From Operations	Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows: Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 (amounts in thousands) Revenues: Nurse and Allied Staffing $ 172,048 $ 152,677 $ 340,813 $ 301,789 Physician Staffing 23,927 29,794 48,380 57,141 Other Human Capital Management Services 3,468 10,146 6,833 19,651 $ 199,443 $ 192,617 $ 396,026 $ 378,581 Contribution income: (a) Nurse and Allied Staffing (b) $ 17,615 $ 12,821 $ 34,405 $ 23,723 Physician Staffing 2,050 2,228 3,603 4,344 Other Human Capital Management Services 69 747 (42 ) 1,349 19,734 15,796 37,966 29,416 Unallocated corporate overhead (b) 9,791 8,455 20,159 16,295 Depreciation 1,059 989 2,064 1,949 Amortization 1,406 983 2,813 1,965 Acquisition and integration costs — 40 — 158 Acquisition-related contingent consideration 183 — 470 — Restructuring costs — 1,007 — 1,007 Impairment charges 24,311 — 24,311 — (Loss) income from operations $ (17,016 ) $ 4,322 $ (11,851 ) $ 8,042 _______________ (a) The Company defines contribution income as income or loss from operations before depreciation, amortization, acquisition and integration costs, acquisition-related contingent consideration, restructuring costs, impairment charges and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance and is provided in accordance with ASC 280, Segment Reporting Topic of the FASB ASC. (b) For the three and six months ended June 30, 2015 , $0.3 million and $0.6 million , respectively, of expenses was reclassified from Nurse and Allied Staffing to unallocated corporate overhead to conform to the current period presentation.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments, as of June 30, 2016 , associated with these agreements with terms of one year or more are as follows: Through Year Ending December 31: (amounts in thousands) 2016 $ 3,657 2017 6,541 2018 5,569 2019 4,365 2020 3,879 Thereafter 15,489 $ 39,500

SUMMARY OF SIGNIFICANT ACCOUN32

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Long-term Debt and Capital Lease Obligations [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of debt issuance costs	$ 0.5	$ 0.5

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands	Apr. 01, 2016	Oct. 30, 2015	Jun. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Business Acquisition [Line Items]
Cash purchase price paid at closing						$ 2,155	$ 0
Acquisition-related contingent consideration				$ 183	$ 0	470	$ 0
Mediscan [Member]
Business Acquisition [Line Items]
Cash purchase price paid at closing		$ 29,900
Cash consideration negotiated		28,000
Fair value of shares		$ 4,700
Fair value of shares (in shares)		349,871
Contingent consideration, range of outcomes, high		$ 7,000
Contingent purchase price liabilities				$ 4,100		$ 4,100
Medical Staffing Network [Member]
Business Acquisition [Line Items]
Contingent purchase price liabilities			$ 2,500
Period of deferred consideration (in months)			21 months
Additional exit liabilities								$ 400
Acquisition-related contingent consideration	$ (2,100)

ACQUISITIONS - Schedule of Pro-

ACQUISITIONS - Schedule of Pro-forma Information (Details) - Mediscan [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)$ / shares
Business Acquisition [Line Items]
Revenue from services | $	$ 399,389
Net income attributable to common shareholders | $	$ 6,629
Net income per share attributable to common shareholders - Basic (in dollars per share) | $ / shares	$ 0.21
Net income per share attributable to common shareholders - Diluted (in dollars per share) | $ / shares	$ 0.16

COMPREHENSIVE INCOME (LOSS) (De

COMPREHENSIVE INCOME (LOSS) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Equity [Abstract]
Cumulative impact of currency fluctuations	$ 1,200,000		$ 1,200,000		$ 1,200,000
Income tax impact related to foreign currency translation adjustments	$ 0	$ 0	$ 0	$ 0

EARNINGS PER SHARE - Components

EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Abstract]
Net income attributable to common shareholders - Basic	$ (17,237)	$ 2,573	$ 1,785	$ 5,507
Interest on Convertible Notes			1,677	1,667
Gain on derivative liability			(12,865)	(2,509)
Net income attributable to common shareholders - Diluted	$ (17,237)	$ 2,573	$ (9,403)	$ 4,665
Weighted average common shares - Basic	32,085	31,398	32,021	31,346
Effective of dilutive shares:
Share-based awards (shares)	0	642	652	641
Convertible Notes (shares)	0	0	3,521	3,521
Diluted weighted average common shares outstanding (shares)	32,085	32,040	36,194	35,508
Net (loss) income per share attributable to common shareholders - Basic
Net income per share attributable to common shareholders - Basic (in dollars per share)	$ (0.54)	$ 0.08	$ 0.06	$ 0.18
Net (loss) income per share attributable to common shareholders - Diluted
Net income per share attributable to common shareholders - Diluted (in dollars per share)	$ (0.54)	$ 0.08	$ (0.26)	$ 0.13

EARNINGS PER SHARE - Antildilut

EARNINGS PER SHARE - Antildilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Convertible Notes and Share-based Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	4,146,517	3,725,326	18,798	174,485

GOODWILL AND OTHER INTANGIBLE38

GOODWILL AND OTHER INTANGIBLES - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 79,240	$ 85,232
Accumulated Amortization	41,232	38,419
Intangible assets subject to amortization, net carrying amount	38,008	46,813
Goodwill	77,376	95,096
Trade names	35,502	36,101
Intangible assets not subject to amortization, net	112,878	131,197
Database [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	31,225	31,225
Accumulated Amortization	15,148	14,150
Intangible assets subject to amortization, net carrying amount	16,077	17,075
Customer Relationships [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	41,212	47,204
Accumulated Amortization	22,382	20,734
Intangible assets subject to amortization, net carrying amount	18,830	26,470
Noncompete Agreements [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,603	3,603
Accumulated Amortization	3,506	3,486
Intangible assets subject to amortization, net carrying amount	97	117
Trade names, definite lived [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,200	3,200
Accumulated Amortization	196	49
Intangible assets subject to amortization, net carrying amount	$ 3,004	$ 3,151

GOODWILL AND OTHER INTANGIBLE39

GOODWILL AND OTHER INTANGIBLES - Impairment Testing (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Finite-Lived Intangible Assets [Line Items]
Non-cash impairment charges	$ 24,311	$ 0	$ 24,311	$ 0
Impairment related to goodwill			17,720
Physician Staffing [Member]
Finite-Lived Intangible Assets [Line Items]
Non-cash impairment charges	24,300		24,300
Impairment related to goodwill	17,700		$ 17,720
Physician Staffing [Member] | Income Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Discount rate percentage			11.50%
Terminal value growth rate percentage			3.00%
Physician Staffing [Member] | Market Approach Valuation Technique [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Total Enterprise Value/EBITDA ratio			7.5
Physician Staffing [Member] | Market Approach Valuation Technique [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Total Enterprise Value/EBITDA ratio			8.5
Physician Staffing [Member] | Income and Market Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Discrete forecast period (in years)			10 years
Physician Staffing [Member] | Income and Market Approach Valuation Technique [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted percentage applied			50.00%
Physician Staffing [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment related to finite lived assets	6,000		$ 6,000
Physician Staffing [Member] | Customer Relationships [Member] | Income Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Discount rate percentage			13.50%
Physician Staffing [Member] | Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment related to indefinite lived assets	$ 600		$ 600

GOODWILL AND OTHER INTANGIBLE40

GOODWILL AND OTHER INTANGIBLES - Annual Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 2,087
2,017	4,140
2,018	4,055
2,019	4,019
2,020	3,914
Thereafter	19,793
Intangible assets subject to amortization, net carrying amount	$ 38,008	$ 46,813

GOODWILL AND OTHER INTANGIBLE41

GOODWILL AND OTHER INTANGIBLES - Goodwill Rollforward (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Goodwill, beginning		$ 95,096
Aggregate goodwill acquired		364,717	$ 364,717
Sale of CCE		(9,889)	(9,889)
Accumulated impairment loss	$ (277,452)	(277,452)	(259,732)
Impairment charges		(17,720)
Goodwill, ending	77,376	77,376	95,096
Nurse And Allied Staffing [Member]
Goodwill [Roll Forward]
Goodwill, beginning		42,273
Aggregate goodwill acquired		302,005	302,005
Sale of CCE		0	0
Accumulated impairment loss	(259,732)	(259,732)	(259,732)
Impairment charges		0
Goodwill, ending	42,273	42,273	42,273
Physician Staffing [Member]
Goodwill [Roll Forward]
Goodwill, beginning		43,405
Aggregate goodwill acquired		43,405	43,405
Sale of CCE		0	0
Accumulated impairment loss	(17,720)	(17,720)	0
Impairment charges	(17,700)	(17,720)
Goodwill, ending	25,685	25,685	43,405
Other Human Capital Management Services [Member]
Goodwill [Roll Forward]
Goodwill, beginning		9,418
Aggregate goodwill acquired		19,307	19,307
Sale of CCE		(9,889)	(9,889)
Accumulated impairment loss	0	0	0
Impairment charges		0
Goodwill, ending	$ 9,418	$ 9,418	$ 9,418

DEBT - Long- Term Debt (Detail

DEBT - Long- Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Capital lease obligations	$ 47	$ 94
Total debt	85,519	96,431
Less current portion	(2,033)	(8,071)
Long-term Debt and Capital Lease Obligations	83,486	88,360
Unamortized Discount and Debt Issuance Costs	(5,748)	(7,059)
Unamortized Discount and Debt Issuance Costs, Noncurrent	(5,748)	(7,059)
Revolving Credit Facility [Member] | Senior Secured Asset-Backed [Member]
Debt Instrument [Line Items]
Debt	0	8,000
Unamortized Discount and Debt Issuance Costs	0	$ 0
Weighted average interest rate		2.41%
Senior Debt [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Debt	40,000	$ 0
Unamortized Discount and Debt Issuance Costs	$ (406)	0
Interest Rate	2.71%
Subordinated Debt [Member] | Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt	$ 0	30,000
Unamortized Discount and Debt Issuance Costs	0	$ (1,052)
Interest Rate		5.75%
Convertible Notes [Member] | 8% Convertible Notes [Member]
Debt Instrument [Line Items]
Debt	25,000	$ 25,000
Unamortized Discount and Debt Issuance Costs	$ (5,342)	$ (6,007)
Interest Rate	8.00%	8.00%
Convertible Notes [Member] | Convertible Note Derivative Liability [Member]
Debt Instrument [Line Items]
Debt	$ 20,472	$ 33,337
Unamortized Discount and Debt Issuance Costs	$ 0	$ 0

DEBT - Debt Maturities (Details

DEBT - Debt Maturities (Details) $ in Thousands	Jun. 30, 2016USD ($)
Capital Lease Obligations [Abstract]
2,016	$ 24
2,017	13
2,018	8
2,019	2
2,020	0
Thereafter	0
Total	47
Term Loan [Member]
Long-term Debt, Fiscal Year Maturity [Abstract]
2,016	1,000
2,017	2,500
2,018	3,000
2,019	3,500
2,020	4,000
Thereafter	26,000
Total	40,000
Convertible Notes [Member]
Long-term Debt, Fiscal Year Maturity [Abstract]
2,016	0
2,017	0
2,018	0
2,019	0
2,020	25,000
Thereafter	0
Total	$ 25,000

DEBT - Consolidated Net Leverag

DEBT - Consolidated Net Leverage Ratio (Details) - Credit Agreement [Member]	6 Months Ended
	Jun. 30, 2016
Covenant Term 1 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.25%
Covenant Term 1 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 1 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 1 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 1 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	0.75%
Covenant Term 1 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	1.50
Covenant Term 2 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%
Covenant Term 2 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.00%
Covenant Term 2 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.00%
Covenant Term 2 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.00%
Covenant Term 2 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.00%
Covenant Term 2 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	1.50
Covenant Term 2 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2
Covenant Term 3 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%
Covenant Term 3 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%
Covenant Term 3 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%
Covenant Term 3 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%
Covenant Term 3 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.25%
Covenant Term 3 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2
Covenant Term 3 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2.50
Covenant Term 4 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.35%
Covenant Term 4 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.50%
Covenant Term 4 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.50%
Covenant Term 4 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.50%
Covenant Term 4 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.50%
Covenant Term 4 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2.50
Covenant Term 4 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	3
Covenant Term 5 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.40%
Covenant Term 5 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.75%
Covenant Term 5 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.75%
Covenant Term 5 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.75%
Covenant Term 5 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 5 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	3

DEBT - Narrative (Details)

DEBT - Narrative (Details)	Jun. 22, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)financial_covenant	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Prepayment penalty	$ 600,000
Loss on early extinguishment of debt		$ 1,568,000	$ 0	$ 1,568,000	$ 0
Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Loss on early extinguishment of debt		$ 1,600,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Interest rate increase (decrease) (percent)				2.00%
Quarterly commitment fee on the average daily unused portion (percent)				0.30%
Number of financial covenants | financial_covenant				2
Credit Agreement [Member] | Senior Debt [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 40,000,000
Percentage of principal payment for first four installments	1.25%
Percentage of principal payment for next eight installments	1.875%
Percentage of principal payment for remaining installments	2.50%
Credit Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Consolidated Fixed Charge Coverage Ratio		1.50		1.50
Credit Agreement [Member] | LIBOR [Member] | Senior Debt [Member]
Debt Instrument [Line Items]
Interest margin				2.25%
Revolving Credit Facility [Member] | First Lien Loan Agreement [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity						$ 85,000,000
Subfacility loans percentage up to aggregate revolver commitments (percent)						10.00%
Line of credit, subfacility for standby letters of credit						$ 35,000,000
Letters of credit rolled and issued under new facility	$ 23,100,000
Revolving Credit Facility [Member] | Second Lien Term Loan [Member] | Subordinated Debt [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity						$ 30,000,000
Line of credit facility, term (in years)						5 years
Revolving Credit Facility [Member] | Second Lien Term Loan [Member] | Period July 1, 2015 through June 30, 2016 [Member] | Subordinated Debt [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed						103.00%
Revolving Credit Facility [Member] | Second Lien Term Loan [Member] | Period July 1, 2016 through June 30, 2017 [Member] | Subordinated Debt [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed						102.00%
Revolving Credit Facility [Member] | Second Lien Term Loan [Member] | After June 30, 2017 [Member] | Subordinated Debt [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed						100.00%
Revolving Credit Facility [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	100,000,000
Line of credit, subfacility for standby letters of credit	35,000,000
Sub facility for swingline loans	15,000,000
Additional capacity	50,000,000
Letters of credit outstanding		$ 23,100,000		$ 23,100,000
Line of credit outstanding	$ 76,900,000
Revolving Credit Facility [Member] | Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Interest margin				2.25%
Fiscal Quarters Ending September 30, 2016 through June 30, 2017 [Member] | Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated Net Leverage Ratio		3.50		3.50
Fiscal Quarters Ending September 30, 2017 through June 30, 2018 [Member] | Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated Net Leverage Ratio		3.25		3.25
Each Fiscal Quarter Ending Thereafter [Member] | Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated Net Leverage Ratio		3		3

DEBT - Private Placement of Con

DEBT - Private Placement of Convertible Notes Narrative (Details) - Convertible Senior Notes [Member]	6 Months Ended
	Jun. 30, 2016instrumentd$ / shares
Debt Instrument [Line Items]
Common stock, par value (in usd per share)	$ 0.0001
Debt conversion price (in usd per share)	$ 7.10
Debt instrument, convertible, number of equity instruments | instrument	3,521,126
Debt Instrument, convertible, threshold period following issuance date (in years)	3 years
Debt instrument, convertible, threshold percentage of stock price trigger	125.00%
Debt instrument, convertible, threshold trading days | d	20
Debt instrument, convertible, threshold consecutive trading days	30 days
Interest rate (percent)	8.00%
Debt instrument, interest, percent paid in kind, maximum	4.00%
Convertible debt redeemed after permissible date, redemption premium, percent of principal	15.00%
Convertible debt redeemed before permissible date, redemption premium, percent of principal	115.00%
Treasury Rate [Member]
Debt Instrument [Line Items]
Convertible debt, basis spread on discount rate on redemption, percentage	0.50%

CONVERTIBLE NOTES DERIVATIVE 47

CONVERTIBLE NOTES DERIVATIVE LIABILITY (Details)	6 Months Ended
	Jun. 30, 2016$ / shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Closing share price (in usd per share)	$ 13.92
Conversion price (in usd per share)	$ 7.10
Risk-free rate (as a percentage)	0.91%
Expected volatility (as a percentage)	40.00%
Dividend yield (as a percentage)	0.00%
Expected life (in years)	4 years

CONVERTIBLE NOTES DERIVATIVE 48

CONVERTIBLE NOTES DERIVATIVE LIABILITY - Narrative (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase or decrease in valuation of embedded derivative liability due to dollar change in stock price	$ 3.3
Increase or decrease in valuation of embedded derivative liability due to percentage change in interest rates	$ 0.8
Embedded Derivative Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in stock price (in usd per share) | $ / shares	$ 1
Change in interest rates (as a percentage)	1.00%

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Fair Value Measurement [Line Items]
Non-cash impairment charges	$ 24,311	$ 0	$ 24,311	$ 0
Minimum [Member]
Fair Value Measurement [Line Items]
Threshold period, past due for payment of services provided (in days)			15 days
Maximum [Member]
Fair Value Measurement [Line Items]
Threshold period, past due for payment of services provided (in days)			60 days
Physician Staffing [Member]
Fair Value Measurement [Line Items]
Non-cash impairment charges	$ 24,300		$ 24,300
Non-cash impairment charges, net of tax			$ 17,300

FAIR VALUE MEASUREMENTS - Estim

FAIR VALUE MEASUREMENTS - Estimated Fair values Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Inputs, Level 1 [Member] | Deferred compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	$ 1,362	$ 1,412
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase price liabilities	4,139	3,686
Fair Value, Inputs, Level 3 [Member] | Convertible Notes, Derivative Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible Notes derivative liability	$ 20,472	$ 33,337

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Contingent Consideration Liability [Member]
Convertible Note Derivative Liability
Beginning balance	$ 3,956	$ 3,686
Payments		(17)
Accretion expense	183	287
Valuation gain for the period	0	0
Ending balance	4,139	3,956
Derivative Financial Instruments, Liabilities [Member]
Convertible Note Derivative Liability
Beginning balance	16,901	33,337
Payments		0
Accretion expense	0	0
Valuation gain for the period	3,571	(16,436)
Ending balance	$ 20,472	$ 16,901

FAIR VALUE MEASUREMENTS - Est52

FAIR VALUE MEASUREMENTS - Estimated Fair Values Assets and Liabilities Measured on Non-Recurring Basis (Details) - Physician Staffing [Member] - Fair Value, Measurements, Nonrecurring [Member] - Fair Value, Inputs, Level 3 [Member] $ in Thousands	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill	$ 25,685
Trade names	15,000
Customer relationships	$ 1,300

FAIR VALUE MEASUREMENTS - Finan

FAIR VALUE MEASUREMENTS - Financial Instrument that were not Measured at Fair Value (Details) - Fair Value, Inputs, Level 2 [Member] - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Second Lien Term Loan, Net [Member] | Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	$ 0	$ 28,948
Second Lien Term Loan, Net [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	0	30,600
Term Loan, Net [Member] | Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	39,593	0
Term Loan, Net [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	39,593	0
Convertible Notes, Net [Member] | Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	19,658	18,993
Convertible Notes, Net [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	28,500	23,250
Senior Secured Asset-Based Loan [Member] | Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	0	8,000
Senior Secured Asset-Based Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	$ 0	$ 8,000

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares left remaining to repurchase under the plan (up to)	942,443			942,443
Stock repurchase program, authorized amount (up to)	$ 2,500,000			$ 2,500,000
Number of shares of common stock outstanding	32,198,575			32,198,575
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1,100,000		$ 800,000	$ 1,800,000	$ 1,200,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				246,020
Vested in period, net (in shares)	164,274		165,842	215,365	180,301
Restricted Stock [Member] | Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				246,020
Performance Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				202,442
Performance Stock [Member] | Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				202,442
Level of performance attained and approved (percent)		100.00%
Shares issued in period		148,178

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of Restricted Stock and Performance Shares (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Restricted Stock [Member]
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) | shares	586,488
Granted (in shares) | shares	246,020
Vested (in shares) | shares	(259,951)
Forfeited (in shares) | shares	(12,667)
Unvested restricted stock awards, Ending balance (in shares) | shares	559,890
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) | $ / shares	$ 7.82
Granted (in dollars per share) | $ / shares	12.01
Vested (in dollars per share) | $ / shares	7.06
Forfeited (in dollars per share) | $ / shares	10.85
Unvested restricted stock awards, Ending balance (in dollars per share) | $ / shares	$ 9.95
Performance Stock [Member]
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) | shares	234,138
Granted (in shares) | shares	202,442
Vested (in shares) | shares	0
Forfeited (in shares) | shares	(9,334)
Unvested restricted stock awards, Ending balance (in shares) | shares	427,246
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) | $ / shares	$ 9.81
Granted (in dollars per share) | $ / shares	11.63
Vested (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	11.79
Unvested restricted stock awards, Ending balance (in dollars per share) | $ / shares	$ 10.63

SEGMENT DATA - Narrative (Detai

SEGMENT DATA - Narrative (Details)	6 Months Ended
	Jun. 30, 2016segment
Segment Reporting [Abstract]
Number of operating segments	3

SEGMENT DATA - Information on O

SEGMENT DATA - Information on Operating Segments and Reconciliation to Loss From Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	$ 199,443	$ 192,617	$ 396,026	$ 378,581
Contribution income	19,734	15,796	37,966	29,416
Unallocated corporate overhead	9,791	8,455	20,159	16,295
Depreciation	1,059	989	2,064	1,949
Amortization	1,406	983	2,813	1,965
Acquisition and integration costs	0	40	0	158
Acquisition-related contingent consideration	183	0	470	0
Restructuring costs	0	1,007	0	1,007
Impairment charges	24,311	0	24,311	0
(Loss) income from operations	(17,016)	4,322	(11,851)	8,042
Nurse and allied staffing [Member] | Scenario, Adjustment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Contribution income		(300)		(600)
Physician staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Impairment charges	24,300		24,300
Operating Segments [Member] | Nurse and allied staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	172,048	152,677	340,813	301,789
Contribution income	17,615	12,821	34,405	23,723
Operating Segments [Member] | Physician staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	23,927	29,794	48,380	57,141
Contribution income	2,050	2,228	3,603	4,344
Operating Segments [Member] | Other human capital management services [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	3,468	10,146	6,833	19,651
Contribution income	$ 69	$ 747	$ (42)	$ 1,349

COMMITMENTS AND CONTINGENIES (D

COMMITMENTS AND CONTINGENIES (Details) $ in Thousands	Jun. 30, 2016USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	$ 3,657
2,017	6,541
2,018	5,569
2,019	4,365
2,020	3,879
Thereafter	15,489
Total future minimum lease payments	$ 39,500

INCOME TAXES (Details)

INCOME TAXES (Details) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)
Income Tax Disclosure [Abstract]
Effective tax rate (percentage)	28.00%	155.80%
Effective income tax rate continuing operations excluding discrete items (percentage)	27.20%	151.30%
Unrecognized tax benefits	$ 0.9	$ 0.9
Unrecognized tax benefits that would impact effective tax rate	$ 4.3	4.3
Gross increase to current year unrecognized tax benefits related to federal and state tax issues		$ 0.5
Income tax examination years subject to examination		2004, 2005, 2008, and 2010 through 2015

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Revenue from related parties	$ 1.3	$ 4	$ 2.7	$ 7
Accounts receivable from related parties	0.6		0.6		$ 0.6
InteliStaf [Member]
Related Party Transaction [Line Items]
Revenue from related parties	$ 2.9	$ 2.2	$ 6	$ 4.3
Joint venture, percent ownership	68.00%		68.00%
Receivable balance with joint venture	$ 1.5		$ 1.5		1.4
Payable balance with joint venture	0.1		0.1		$ 0.2
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Rent expense	$ 0.1		$ 0.2